Bioelectronics Corp (BIEL)

[GetSeriousOK]

Blah blah. Blah blah blah. Blah. Blah. Revenues?

When a developmental biotech gets FDA clearance, it's time to stop being developmental and start generating revenues.

Will Q4 2021 be profitable? Unlikely. Will Revenues be higher than $400,000? Unlikely.

KT Tape and DonJoy aren't doing enough to promote or advertise their ActiPatch products. A couple of mentions on Twitter are not going to be found by anyone who doesn't already know about the products.

Future projects? Whoopie. Future trials, future research, blah blah blah? Woo hoo. More OEM Partners? Not seeing the OEM Partner business model working so far. This ticker is going nowhere until the company generates some explosive revenues. And if KT Tape and DonJoy aren't going to ramp up promotion of their ActiPatch products, it's never going to happen.

Because Bob down the street might have chronic knee pain but he's never going to see a press release and he's never going to see a KT Tape tweet.